Capital International Sarl Acquires 1,834 Shares of Novo Nordisk A/S (NYSE:NVO)

Capital International Sarl grew its position in Novo Nordisk A/S (NYSE:NVO) by 7.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 27,066 shares of the company’s stock after buying an additional 1,834 shares during the period. Capital International Sarl’s holdings in Novo Nordisk A/S were worth $3,475,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. HB Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 32.1% in the 4th quarter. HB Wealth Management LLC now owns 12,941 shares of the company’s stock valued at $1,339,000 after buying an additional 3,145 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 36.1% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 489,510 shares of the company’s stock worth $50,640,000 after purchasing an additional 129,739 shares during the period. Pacer Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 98.0% during the fourth quarter. Pacer Advisors Inc. now owns 29,706 shares of the company’s stock worth $3,073,000 after purchasing an additional 14,702 shares during the period. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after purchasing an additional 100 shares during the period. Finally, PFG Investments LLC grew its stake in shares of Novo Nordisk A/S by 3.4% during the fourth quarter. PFG Investments LLC now owns 14,143 shares of the company’s stock worth $1,463,000 after purchasing an additional 469 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on NVO shares. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective for the company. Argus lifted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, July 1st. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Trading Down 0.9 %

NVO stock traded down $1.14 during midday trading on Friday, hitting $126.72. 3,178,103 shares of the company’s stock were exchanged, compared to its average volume of 4,424,668. The stock’s fifty day moving average price is $138.69 and its 200-day moving average price is $128.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The company has a market cap of $568.66 billion, a PE ratio of 43.70, a price-to-earnings-growth ratio of 1.32 and a beta of 0.41. Novo Nordisk A/S has a one year low of $77.96 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.